Ekspresja niektórych molekularnych markerów immunohistochemicznych i ocena ich znaczenia prognostycznego w rakach płaskonabłonkowych jamy ustnej i wargi
Journal Title: Otolaryngologia Polska - Year 2008, Vol 62, Issue 2
Abstract
Introduction: Head and neck cancer treatment optimization and individualization has become possible due to the implementation of the prognostic and predictive molecular markers in diagnostics. Aim: The aim of this study was an attempt to determine which of the investigated molecular markers may have prognostic and predictive value in head and neck cancers. Materials and Methods: The paraffi n blocks from 47 patients with oral and lip squamous cell carcinoma (SCC) after surgical treatment in the Institute of Oncology in Gliwice in the period of 1998–2002 were investigated. For immunohistochemical studies the DAKO monoclonal antibodies were used: p53, Ki67, Cyclin D1, Cathepsin B and Cox2- Cayman Chemical antibody. Staining reactions were evaluated at 400x magnifi cation. The average percent of staining cells was estimated in every case in the groups of patients with (N+) and without (No) node metastases. The results were subsequently juxtaposed with selected clinical and histological parameters. Statistical analysis was performed with MannWhitney and Kruskal-Wallis tests and the log rank test with a signifi cance level of 0.05 (p = 0,05). Results: Signifi cantly higher expression of Ki67 in N+ patients (p = 0,010) were recorded, although average staining in the group of treated and the group of unhealed patients was statistically insignifi cant. Cathepsin B expression (<20% and > 20%) was correlated with 3 year-long survival and a slight higher average staining (33,5%) in unhealed in comparison with treated patients (29,0%) was notified. Everage expression of p53 in unhealed patients (33,1%) was slightly higher than in treated ones (28,4%). Weaker Cyclin D1 expression (<10%) correlated with higher disease free survival. Average Cycline D1 staining in the groups of unhealed patients (19,6%) was higher than in the treated ones (12,0%). There were no significant differences in COX-2 staining in correlation with clinical and histological parameters. Conclusions: Lower expression of Cyclin D1 and Cathepsin B in neoplastic cells correlated with higher percentage of disease free survival what suggests the prognostic value of these markers. Higher proliferation activity of primary tumor neoplastic cells correlated with node metastases what may has the predictive value in the course of the disease.The different markers expressions observed in the different oral cavity localizations confi rm the necessity to select patients for further investigations with respect to uniform disease changes topography.
Authors and Affiliations
Magdalena Jaworska, Zofia Kołosza, Joanna Liszka, Barbara Nikiel, Maria Goleń, Dariusz Lange, Wojciech Ścierski, Grzegorz Namysłowski
Papillary thyroid carcinoma in thyroglossal duct cyst
Introduction: Thyroglossal duct cyst is one of the most common congenital malformation in the neck area, but malignant neoplasms of the thyroglossal duct cyst are rare, about 1–1,5% cases of TDC. The papillary thyroid ca...
Embolization of carotid arteria branch in stanching of nasal bleeding
Background: Epistaxis is a common clinical problem, especially in otolaryngology. This disorder affects equally both genders. Most cases manifest as spontaneous nasal bleeding. It can also appear as a result of trauma, h...
Guzy tylnego dołu czaszki jako przyczyna nagłego pogorszenia słuchu i/lub wystąpienia zawrotów głowy
SUMMARY Introduction: The aim of the work was to analyse sudden deterioration of hearing and/or vertigo occurrence as an early symptom of posterior cranial fossa tumours. Material and methods: Among 1.394 people who repo...
Szkliwiak zatoki szczękowej – opis przypadku
Ameloblastoma (adamantinoma) is a benign neoplasm deriving from the enamel organ. Its etiology has not been ultimately determined. It constitutes about 1% of all head and neck tumours, and about 11% of teeth-originating...
Sprawozdanie z II Kongresu Onkologii Polskiej „Jakość leczenia onkologicznego wyzwaniem XXI wieku” Poznań 25–28 X 2006 r.